Clinical and Translational User Group Meetings +
Going beyond: Molecular evidence for off-label therapy use
92 views
Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN Digital Insights explains
•Using molecular pathways to expand therapy options
•Identifying evidence-based therapy options for cancer patients for whom there is no on-label therapy
•Providing confidence with expert-curated, oncologist-reviewed treatment strategies
•Using molecular pathways to expand therapy options
•Identifying evidence-based therapy options for cancer patients for whom there is no on-label therapy
•Providing confidence with expert-curated, oncologist-reviewed treatment strategies
Related videos
Clinical and Translational User Group Meetings +
Confidence and trust: Deliver valuable clinical insights with high-quality knowledge
Ben Turner, Director of Bioinformatics Enterprise Solutions, QIAGEN Digital...
Clinical and Translational User Group Meetings +
Generate oncologist-ready clinical reports from comprehensive panels
Ruth Burton, Ph.D., Clinical Application Specialist, QIAGEN Digital Insights...
Clinical and Translational User Group Meetings +
Secondary analysis: From NGS data to variant identification and visualizationin the cloud
Ajay Athavale, Ph.D., Senior manager, Clinical services, QIAGEN Digital...
Clinical and Translational User Group Meetings +
From NGS data to Variant identification and visualization
Cristian Cosentino, Ph.D., Senior Field Bioinformatics Application...